GlobeStar Therapeutics Corporation
GSTC · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $2 | $38 |
| Gross Profit | $0 | $0 | -$2 | -$38 |
| % Margin | – | – | – | -48,837.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1,864 | $1,265 | $9,092 | $266 |
| SG&A Expenses | $1,864 | $1,265 | $9,092 | $266 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,864 | $1,265 | $9,092 | $266 |
| Operating Income | -$1,864 | -$1,265 | -$9,094 | -$304 |
| % Margin | – | – | – | -394,805.2% |
| Other Income/Exp. Net | -$85 | -$223 | -$707 | -$238 |
| Pre-Tax Income | -$1,949 | -$1,488 | -$9,802 | -$542 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,949 | -$1,488 | -$9,802 | -$542 |
| % Margin | – | – | – | -703,896.1% |
| EPS | -0.002 | -0.002 | -0.02 | -0.002 |
| % Growth | 0% | 88.2% | -1,027.8% | – |
| EPS Diluted | -0.002 | -0.002 | -0.02 | -0.002 |
| Weighted Avg Shares Out | 827,325 | 628,540 | 482,091 | 298,091 |
| Weighted Avg Shares Out Dil | 827,324 | 628,540 | 482,091 | 298,091 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $92 | $70 | $287 | $238 |
| Depreciation & Amortization | $1,864 | $1 | $1 | $1 |
| EBITDA | $7 | -$1,264 | -$9,093 | -$302 |
| % Margin | – | – | – | -392,207.8% |